Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation

1 Jan 2020

Abstract excerpt

NVP-BEZ235 is a novel dual PI3K/mTOR inhibitor, currently in phase 1/2 clinical trials, exhibiting clinical efficiency in treatment of numerous malignancies including thyroid cancer. Cancer cells harboring mutant p53 was widely reported to be blunt to pharmaceutical therapies. However, whether this genotype dependent effect also presents in thyroid cancer when treated with NVP-BEZ235 remains unknown. Therefore,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Thyroid Cancer Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32025215
DOI: 10.7150/ijbs.37592

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulationPMID 32025215Read ↗

CircTP53 promotes the proliferation of thyroid cancer via targeting miR-1233-3p/MDM2 axisSemantic proximity Read ↗

Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells.Semantic proximity Read ↗

SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathwaysSemantic proximity Read ↗

Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.Semantic proximity Read ↗

PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma.Semantic proximity Read ↗

Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways.Semantic proximity Read ↗

Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.Semantic proximity Read ↗

The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimensSemantic proximity Read ↗

Downregulated LRRK2 gene expression inhibits proliferation and migration while promoting the apoptosis of thyroid cancer cells by inhibiting activation of the JNK signaling pathwaySemantic proximity Read ↗

p53-independent p21 induction by MELK inhibitionSemantic proximity Read ↗

Synergistic Effect of Metformin and Vemurufenib (PLX4032) as a Molecular Targeted Therapy in Anaplastic Thyroid Cancer – An In Vitro StudySemantic proximity Read ↗

New Insights in Thyroid Cancer and p53 Family Proteins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.